ISRG logo

ISRG Intuitive Surgical Inc

$414.44
$9.26
(2.29%)
Today
33

Bearish Sentiment

How do you feel about ISRG?

Loading...
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
OPKO Health eyes growth from RAYALDEE, partner revenues and a leaner BioReference, while pipeline and reimbursement risks remain key concerns.
Zacks
RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection
Revvity launches a CE-IVDR-certified automated T1D screening kit for children, expanding its GSP platform from newborn screening into early childhood.
Zacks
Here's How Much $1000 Invested In Intuitive Surgical 10 Years Ago Would Be Worth Today
Intuitive Surgical (NASDAQ:ISRG) has outperformed the market over the past 10 years by 3.99% on an annualized basis producing an average annual return of 17.48%. Currently, Intuitive Surgical has a market capitalizationread more...
Benzinga
Here's Why You Should Retain Baxter Stock in Your Portfolio for Now
BAX's portfolio reset and growth in connected care and advanced surgery support prospects, but margins, Novum IQ and China pricing remain risks.
Zacks
COO Unveils New Innovation Hub & Lens Launch Plans to Aid CooperVision
The Cooper Companies opens a global innovation hub in England and unveils six contact lens programs to support sustainable long-term growth.
Zacks
Buy 3 AI-Powered Medical Stocks to Strengthen Your Portfolio in Q4
AI adoption is reshaping medical devices, with ISRG, TEM and TMO leveraging AI to advance precision medicine and drug development.
Zacks
Intuitive Surgical Stock Has Plunged 29% This Year. Is the Market Overreacting?
Key PointsIntuitive Surgical's stock has declined sharply this year due to several factors...
Nasdaq News: Markets
Intuitive Surgical vs. Stryker: Which MedTech Stock Is the Better Buy Now?
ISRG's rapid procedure growth, expanding robotics ecosystem and recurring revenues highlight its growth path amid MedTech shifts.
Zacks
Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDx
NTRA wins Japan PMDA approval for Signatera in muscle-invasive bladder cancer, supporting treatment decisions and a planned 2027 commercial launch.
Zacks